Genzyme BioSurface Deal Approved

19 December 1994

Shareholders of Genzyme Corp and BioSurface have approved the planned acquisition of the latter by the former, first announced earlier this year (Marketletter August 1), and merge it into the new Genzyme Tissue Repair Division. As part of the transaction, Genzyme shareholders also approved the issuance of a new class of common stock that will represent the business of the Tissue Repair Division.

The Tissue Repair Division is a fully integrated business with annual sales of $6 million from the Epicel skin graft product. It will soon start marketing an autologous cultured cartilage cell product. It also has four other products in clinical development for seven indications. Among these are the Vianain debriding agent, designed to remove non-viable tissue from burns and skin ulcers; TGF-

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight